| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The precise molecular target of WAY-299801 has not been fully elucidated, but the compound is characterized as an antibacterial agent with potent antimycobacterial activity. It is used as a tool compound in tuberculosis research to study drug resistance mechanisms and to screen for novel anti-mycobacterial candidates. Its activity against clinically isolated Mycobacterium tuberculosis strains makes it valuable for tuberculosis drug discovery.
|
|---|---|
| ln Vitro |
WAY-299801 displays potent in vitro antimycobacterial activity against certain mycobacterial strains and clinical isolates of Mycobacterium tuberculosis. In vitro studies demonstrate significant inhibitory effects against multiple mycobacterial strains. The compound's antibacterial activity has been characterized in various assay systems. WAY-299801 is frequently used in anti-tuberculosis drug development and the study of drug resistance mechanisms.
|
| ln Vivo |
In vivo activity of WAY-299801 has not been extensively reported in the available literature. The compound is primarily used as an in vitro tool for antibacterial and antimycobacterial research. Further studies would be required to evaluate its in vivo efficacy, pharmacokinetics, and therapeutic potential in animal models of tuberculosis or other bacterial infections.
|
| Enzyme Assay |
The antibacterial activity of WAY-299801 is assessed using standard antimicrobial susceptibility testing methods. Minimum inhibitory concentrations (MICs) are determined using broth microdilution or agar dilution methods according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Mycobacterial strains, including Mycobacterium tuberculosis clinical isolates, are cultured in appropriate media. WAY-299801 is tested at varying concentrations, and MIC values are determined after incubation. Activity against multiple mycobacterial strains is evaluated.
|
| Cell Assay |
Cellular activity of WAY-299801 is evaluated in mycobacterial cultures grown in liquid or solid media. Mycobacterial strains are cultured to logarithmic phase and exposed to varying concentrations of WAY-299801. Bacterial growth is monitored by optical density measurement or colony counting. The compound's ability to inhibit the growth of multiple mycobacterial strains and clinical isolates of Mycobacterium tuberculosis is assessed.
|
| Animal Protocol |
In vivo evaluation of WAY-299801 would typically involve mouse models of Mycobacterium tuberculosis infection. Mice would be infected with a virulent strain of M. tuberculosis via aerosol or intravenous injection. WAY-299801 would be administered orally or intraperitoneally at various doses. Bacterial burden in lungs and spleen would be assessed by colony-forming unit (CFU) counts. Survival and clinical signs would be monitored. Such studies have not been extensively reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of WAY-299801 have not been extensively characterized in the available literature. The compound has a molecular formula of C15H16N4O2 and a molecular weight of 284.31. It is stored as powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year. The compound is typically shipped on dry ice or at ambient temperature. Further pharmacokinetic characterization would be required for development.
|
| Toxicity/Toxicokinetics |
Toxicological data for WAY-299801 are limited to research applications. The compound is for research use only and not intended for therapeutic use. As an antibacterial agent, toxicity would typically be evaluated in the context of the specific cell lines or animal models being studied. Comprehensive toxicology profiling would be required for clinical development.
|
| References |
Mamolo MG, Vio L, Banfi E, Predominato M, Fabris C, Asaro F. Synthesis and antimycobacterial activity of some 2-pyridinecarboxyamidrazone derivatives. Farmaco. 1992 Jul-Aug;47(7-8):1055-66. PMID: 1445613.
|
| Additional Infomation |
WAY-299801 was first reported in Farmaco (1992), 47(7-8), 1055-66. It is also known by the chemical name 2-pyridinecarboximidic acid, 2-[(2,5-dimethoxyphenyl)methylene]hydrazide. The compound is frequently employed in anti-tuberculosis drug development and research into drug resistance mechanisms. Its potent activity against clinically isolated Mycobacterium tuberculosis makes it a valuable tool for tuberculosis research.
|
| Molecular Formula |
C15H16N4O2
|
|---|---|
| Molecular Weight |
284.313142776489
|
| Exact Mass |
284.13
|
| Elemental Analysis |
C, 63.37; H, 5.67; N, 19.71; O, 11.25
|
| CAS # |
146430-05-9
|
| PubChem CID |
9574339
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
373
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=C(C=C1)OC)/C=N/N=C(/C2=CC=CC=N2)\N
|
| InChi Key |
YYGBRKHKDDYDEM-VCHYOVAHSA-N
|
| InChi Code |
InChI=1S/C15H16N4O2/c1-20-12-6-7-14(21-2)11(9-12)10-18-19-15(16)13-5-3-4-8-17-13/h3-10H,1-2H3,(H2,16,19)/b18-10+
|
| Chemical Name |
2-Pyridinecarboximidic acid, 2-[(2,5-dimethoxyphenyl)methylene]hydrazide
|
| Synonyms |
WAY-299801; WAY 299801; WAY299801;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | |
| 5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | |
| 10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
